Chemical Name: 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
CAS Number: 503612-47-3
Molecular Formula: C25H25N5O4
Molecular Weight: 459.49700
Physical and Chemical Properties
Density: 1.42g/cm³
Boiling Point: 770.468ºC at 760 mmHg
Flash Point: 419.764ºC
Refractive Index: 1.705
Indications
Apixaban is primarily used for:
Prophylaxis of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.
Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Reduction in the recurrence of DVT and PE.
Development History
Apixaban originated in the 1990s at DuPont laboratories and has undergone a series of large, multicenter clinical studies across various medical fields.
In 2011, it was the first to be approved in the European Union (including 27 member states, Iceland, and Norway) for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.
